From: The human microglial HMC3 cell line: where do we stand? A systematic literature review
| Immunocytochemistry | ||
| mAbs or immunostaining reagents | Concentration | Final dilution used |
| DAPI (4′,6-diamidino-2-phenylindole, dihydrochloride) (ThermoFisher Cat. N. D1306) | 5 mg/ml | 1/2000 |
| Rhodamine phalloidin (ThermoFisher Cat. N. R415) | 200 U/ml | 1/500 |
|
IBA1 (Abcam Cat. N. ab15690) | 3.5 mg/ml | 1/100 |
| Flow Cytometry | ||
| mAbs | Optimal Ab volume per test (1 × 106) | Final dilution used |
| PE-conjugated anti-GFAP (BD Pharmingen Cat. N. 561,483) | 5 μl | 1/40 |
| PE-conjugated anti-HLA-DR (BD Bioscience Cat. N. 562,304) | 5 μl | 1/50 |
| FITC-conjugated anti-CD14 (BD Pharmingen Cat. n 555,397) | 20 μl | 1/10 |
| PE-conjugated anti-CD11b (eBioscience™ Cat. N. 12–0118-42) | 5 μl | 1/20 |
| PE-conjugated anti CD68 (BD Horizon Cat. N. 564,944) | 5 μl | 1/40 |
| FITC-conjugated anti-HLA-ABC (BD Biosciences Cat. N. 555,552) | 20 μl | 1/10 |